3:42 PM
Mar 02, 2018
 |  BC Extra  |  Company News

ICER panel split on value of CAR Ts

The Institute for Clinical and Economic Review's California Technology Assessment Forum voted that the value of Kymriah tisagenlecleucel was intermediate, while the panel was mixed on whether the value of Yescarta axicabtagene ciloleucel was intermediate or low.

Seven members voted that the value of Kymriah from Novartis AG (NYSE:NVS; SIX:NOVN) has...

Read the full 232 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >